ActiveSight Signs Protein Crystallography Agreement with Novo Nordisk
News Jan 24, 2006
ActiveSight will co-crystallize Novo Nordisk proprietary molecules with proteins expressed by ActiveSight.
"We are very pleased to add a company of Novo Nordisk's stature to our growing customer base," stated Ronald V. Swanson, Ph.D., Chief Scientific Officer for ActiveSight.
"We look forward to supplying their scientists with structural information to accelerate their discovery efforts."
This is the first announced agreement of 2006 for the protein crystallography services provider, which was founded in 2003.
Strong Immune Response in Diseased Corals Potential Trade-OffNews
Researchers have found a correlation between a strong immune response in diseased corals and a lower expression of genes associated with growth and reproduction.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018